Pharmanutra SpA
MIL:PHN
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IT |
|
Pharmanutra SpA
MIL:PHN
|
609m EUR |
Loading...
|
|
| FR |
|
L'Oreal SA
PAR:OR
|
208.6B EUR |
Loading...
|
|
| UK |
|
Unilever PLC
LSE:ULVR
|
116B GBP |
Loading...
|
|
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.6T INR |
Loading...
|
|
| UK |
|
HALEON PLC
LSE:HLN
|
36.5B GBP |
Loading...
|
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
38.5B USD |
Loading...
|
|
| DE |
|
Beiersdorf AG
XETRA:BEI
|
23B EUR |
Loading...
|
|
| JP |
|
Kao Corp
TSE:4452
|
3T JPY |
Loading...
|
|
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.2T INR |
Loading...
|
|
| IN |
|
Dabur India Ltd
NSE:DABUR
|
919.7B INR |
Loading...
|
|
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD |
Loading...
|
Market Distribution
| Min | -40 300% |
| 30th Percentile | 38.1% |
| Median | 52.1% |
| 70th Percentile | 67.8% |
| Max | 1 132% |
Other Profitability Ratios
Pharmanutra SpA
Glance View
Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Pharmanutra SpA is 97.1%, which is above its 3-year median of 96.8%.
Over the last 3 years, Pharmanutra SpA’s Gross Margin has increased from 96.9% to 97.1%. During this period, it reached a low of 94.5% on Dec 31, 2024 and a high of 98.2% on Sep 30, 2023.
